Superficial Punctate Keratoepitheliopathy Under Treatment with Erlotinib and Lapatinib.
10.3341/jkos.2014.55.2.293
- Author:
Eun Kyu OH
1
;
Dong Hyun JO
;
Mee Kum KIM
;
Won Ryang WEE
Author Information
1. Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea. kmk9@snu.ac.kr
- Publication Type:Case Report
- Keywords:
Cancer treatment;
Corneal erosion;
Epidermal growth factor
- MeSH:
Cilia;
Cornea;
Epidermal Growth Factor;
Humans;
Ophthalmic Solutions;
Receptor, Epidermal Growth Factor;
Visual Acuity;
Erlotinib Hydrochloride
- From:Journal of the Korean Ophthalmological Society
2014;55(2):293-297
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To report the corneal superficial punctate keratoepitheliopathy in 2 patients taking the epidermal growth factor receptor (EGFR) inhibitors, erlotinib and lapatinib, respectively. CASE SUMMARY: Case 1, who received erlotinib, showed trichomegaly without touching the cornea and diffuse punctate keratoepitheliopathy. Corneal epitheliopathy and the corresponding symptoms resolved after discontinuation of the drug then recurred with reapplication. Case 2 presented diffuse corneal punctate epithelial erosions that developed without any cilia involvement after the patient was administered lapatinib. The visual acuity of both patients was not severely diminished and keratoepitheliopathy was mostly resolved with the treatment of preservative-free artificial tears and autologous serum eye drops. CONCLUSIONS: Erlotinib and lapatinib are both likely to cause visually tolerable corneal punctate keratoepitheliopathy which can be resolved with appropriate topical treatment.
